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DRUG EVALUATION
Natpara for the treatment of hypoparathyroidism
Gemma Marcucci a, Giuseppe Della Pepab and Maria Luisa Brandia
aBone Metabolic Diseases Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy; bDepartment of Clinical
Medicine and Surgery, Federico II University, Naples, Italy
ABSTRACT
Introduction: Hypoparathyroidism is a rare endocrine disorder characterized by hypocalcaemia and
hyperphosphatemia, due to absent or inappropriately low parathyroid hormone levels. For manage-
ment of chronic hypoparathyroidism, current treatment options involve oral calcium and vitamin D. This
standard treatment cannot resolve all problematic aspects of the disease, such as abnormal bone
remodeling and reduced quality of life, and is associated with long-term complications, including
nephrolithiasis, nephrocalcinosis, renal impairment, cataracts and cerebral calcifications.
Areas covered: In 2015, the FDA (Food and Drug Administration) approved rhPTH (1–84), named
Natpara®, a bioengineered recombinant human PTH, for the management of hypoparathyroidism of any
etiology, except Autosomal Dominant Hypocalcemia, not well controlled with calcium and active
vitamin D. Herein, the authors review its chemistry, pharmacodynamics, pharmacokinetics and clinical
efficacy for hypoparathyroidism.
Expert opinion: Replacement therapy with rhPTH (1–84) is a fundamental step in the treatment of
chronic hypoparathyroidism in cases not well controlled by standard therapy, providing the natural
hormone that is lacking for the maintenance of normal calcium levels, and reducing long-term risks
associated with conventional therapy. Nevertheless, given the chronic nature of the disease, in the
future, further studies will have to be performed to evaluate long-term efficacy and safety of the
drug.
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1. Introduction
Hypoparathyroidism is a rare endocrine disease characterized
by hypocalcaemia and hyperphosphatemia, due to absent or
inappropriately low parathyroid hormone (PTH) levels [1,2].
This disorder can be acquired or hereditary. It results from a
surgical procedure in approximately 75% of patients, and in
the remainder is due to genetic, autoimmune, or unknown
etiologies. The most common acquired form of hypoparathyr-
oidism in adults, caused by surgery, is due to inadvertent or
unavoidable removal of the parathyroid glands or damage to
the parathyroid glands and/or their blood supply [3]. The
second most common cause in adults is autoimmune disease,
either affecting only the parathyroid glands, or multiple other
endocrine glands, such as autoimmune polyglandular syn-
drome type 1-3-4 (APS-1-3-4) or rarely APS-2 [2]. Other forms
of genetic hypoparathyroidism can be in association with
other organ defects or an isolated disorder. Syndromic genetic
forms of hypoparathyroidism include: DiGeorge’s syndrome,
hypoparathyroidism–deafness–renal dysplasia syndrome,
Kenny–Caffey syndrome, hypoparathyroidism–retardation–
dysmorphism syndrome, Kearns–Sayre syndrome, and mito-
chondrial encephalopathy, lactic acidosis, and stroke-like epi-
sode syndrome. Non-syndromic isolated genetic forms
include: familial isolated hypoparathyroidism with autosomal
dominant, recessive or X-linked inheritance, and autosomal
dominant hypocalcemia with hypercalciuria type 1 and 2 [1].
Autosomal dominant hypocalcemia with hypercalciuria type 1
is caused by heterozygous activating mutations of calcium
sensing receptor (CasR), resulting in a decrease of PTH, with
consequent hypocalcemia with relative or absolute hypercal-
ciuria. The recently identified autosomal dominant hypocalce-
mia with hypercalciuria type 2 is caused by heterozygous gain-
of-function missense mutations of the guanine nucleotide
binding protein (G protein) Alpha 11 (GNA11), increasing the
sensitivity to changes in Cao2+ [4]. The remaining cases of
acquired hypoparathyroidism include rare infiltrative diseases
in which the parathyroid glands are affected by metastatic
disease or copper or iron overload, or ionizing radiation expo-
sure [1,2].
Most signs and symptoms of hypoparathyroidism are due to
low serum ionized [Ca2+], altering neurologic, cognitive, muscular,
and cardiac functions [1,2]. The clinical features due to hypocal-
caemia result in highly variable manifestations, such as neuromus-
cular irritability (e.g. tetany, muscle cramping, paraesthesias,
laryngo-, and bronchospasm), central nervous system alterations
(seizures, and altered mental status), cardiac complications (e.g.
congestive heart failure, and prolonged QT interval), other compli-
cations (e.g. calcifications of the basal ganglia, abnormal dentition,
and cataracts) or no symptomatology [2].Moreover, hypoparathyr-
oidism is characterized by a state of marked low bone turnover
with an increased bone mass. The abnormally low bone
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remodeling and dense bone suggests that, in the case of PTH
deficit, bone is hypermature and potentially more subject to frac-
ture thanbonewith appropriate PTH levels [5]. Patients affectedby
hypoparathyroidism frequently report symptoms suggesting
impaired quality of life, including cognitive symptoms such as
‘brain fog’ and inability to concentrate, depression and/or anxiety,
in addition to fatigue, muscle spasms, pain, and paresthesia [1].
Formanagement of chronic hypoparathyroidism, current treat-
ment options involve oral calcium and vitamin D (its metabolites
and analogs) supplementation, and thiazide diuretics, which
reduce urinary calcium excretion. Patients affected by chronic
hypoparathyroidism often require large amounts of calcium and
active forms ormetabolites of vitaminD tomaintain normal serum
calcium levels. Apparently, normalization of serum calcium levels
in response to conventional therapy with calcium and active vita-
min D does not restore the normal physiology of calcium home-
ostasis, and induces hypercalciuria and hyperphosphatemia in
absence of the renal calcium reabsorption and phosphaturia nor-
mally promoted by PTH [2]. Therefore, standard treatment
increases the risk of extra-skeletal calcification and long-term kid-
ney complications [6]. In addition, due to the lack of PTH, bones
typically have abnormal remodeling, and many patients with
hypoparathyroidism complain of reduced quality of life, despite
conventional therapy [7]. These problematic aspects have directed
scientific research to find different therapeutic options.
The first treatment of hypoparathyroidism with use of
bovine PTH extract was attempted 50 years ago in humans,
but failed due to the development of neutralizing antibodies
after several weeks of injection [8]. No further studies were
performed until it became possible to produce PTH by recom-
binant DNA technology. There are two formulations of PTH
that have been studied in hypoparathyroidism: the full-length
molecule, PTH (1–84), and the N-terminal biological active
fragment of the molecule, PTH (1–34), named teriparatide.
Both formulations have been studied as a subcutaneous injec-
tion. Generally, for different pharmacokinetics, PTH (1–84) is
required once daily, while PTH (1–34) is administered by multi-
ple injections per day [9,10]. PTH has been investigated as a
therapy for hypoparathyroidism in several studies since 1996,
in children, and in adults in which hypoparathyroidism
occurred as a thyroid surgery complication, or could be due
to autoimmune disease or genetic mutations. Over the past
two decades, studies of replacement therapy with PTH have
ushered in a new era in the management of this disease, with
an improvement of calcium homeostasis and quality of life,
particularly for those who require large amounts of calcium
and active vitamin D. To date, only in the United States, the
Food and Drug Administration (FDA) has approved recombi-
nant human (rh)PTH (1–84) [rhPTH (1–84)], named Natpara®
(see Box 1), a bioenginerred recombinant human PTH, for the
management of hypoparathyroidism in 2015 [11]. The FDA
indication for this drug is for subjects with hypoparathyroid-
ism of any etiology, with the exception of Autosomal
Dominant Hypocalcemia, which cannot be well controlled on
calcium and active vitamin D. rhPTH (1–84), indeed, has not
been studied in patients with hypoparathyroidism caused by
mutations of CasR. These individuals may have normal levels
of PTH but hypocalcemia, representing a steady state of the
abnormally sensitive CaSR. In these cases, future therapies
might employ calcilytics, which directly modulate the CaSR.
In particular, in accordance with the most recently pub-
lished guidelines, therapy with rhPTH (1–84) is recommended
in case of: oral calcium/vitamin D medications required to
control the serum calcium or symptoms that exceed 2.5 g of
calcium or >1.5 μg of active vitamin D or >3.0 μg of the 1-
alpha vitamin D analog; hypercalciuria, renal stones, nephro-
calcinosis, stone risk, or reduced creatinine clearance or eGFR
(<60 ml/min); hyperphosphatemia and/or calcium–phosphate
product that exceeds 55 mg2 dL2 (4.4 mmol2 L2); gastrointest-
inal tract disorder that is associated with malabsorption; and,
finally, reduced quality of life [8].
This article reviews the pharmacological features, clinical
efficacy, safety, and tolerability of this drug in patients affected
by chronic hypoparathyroidism.
2. rhPTH (1–84) replacement therapy in
hypoparathyroidism
2.1. Chemistry
Natpara® is a synthetic rhPTH (1–84), identical to the full-
length human 84-amino acid protein. It is produced by recom-
binant DNA technology using a strain of Escherichia coli. This
molecule of 84 amino acids is composed by an amino (N)-
terminal structure (34 amino acids) and a carboxyl (C)-terminal
structure (50 amino acids), with a molecular weight of 9425
Da [11].
2.2. Physiological role of PTH
Physiologically, the major function of PTH is to regulate circu-
lating ionized calcium. The effects of PTH on the bone, kid-
neys, and intestine are necessary to maintain serum calcium
within a tight range. PTH also has a reciprocal effect on
phosphate metabolism [12,13], and acts in concert with fibro-
blast growth factor 23 (FGF23) and klotho. In the bone, PTH
stimulates the expression of receptor activator of nuclear fac-
tor k-B ligand (RANKL) by osteoblasts, which induces osteo-
clastogenesis and osteoclastic bone resorption, and reduces
the expression of osteoprotegerin (a RANKL decoy receptor),
mobilizing calcium and phosphorus into the circulation [13]. In
the kidneys, PTH favors conversion of 25-hydroxyvitamin D [25
(OH)D] to 1,25(OH)2D, and promotes calcium reabsorption and
phosphate excretion. 1,25(OH)2D3, in turn, increases intestinal
calcium and phosphate absorption [2,13].
Box 1. Drug summary
Drug name Natpara®
Phase Launched
Indication Hypoparathyroidism
Pharmacology
description
Parathyroid hormone receptor 1 agonist
Route of
administration
Subcutaneous injection
Pivotal trial(s) REPLACE (23), REPEAT (24); RACE (NCT01297309)
(ongoing, but not recruiting participants)
1418 G. MARCUCCI ET AL.
2.3. Pharmacodynamics
rhPTH (1–84) increases serum calcium concentrations in a dose
proportional manner [14]. Clarke et al. investigated a single
subcutaneous injection of rhPTH (1–84) in patients affected by
hypoparathyroidism, with a dose-escalating study of single sub-
cutaneous administration of 50 µg and then 100 µg. Each
patient received a single 50-µg rhPTH (1–84) dose, had at least
a 7-day washout interval, and then received a single 100-µg
rhPTH (1–84) dose. Compared with calcitriol, rhPTH (1–84)
50 µg reduced 24-h calcium excretion and calcium-to-creatinine
ratios by 12% and 23%, respectively, and rhPTH (1–84) 100 µg
reduced them by 26% and 27%. Compared with calcitriol, rhPTH
(1–84) 50 µg increased urinary phosphate excretion and phos-
phate-to-creatinine ratios by 53% and 54%, respectively, and
rhPTH (1–84) 100 µg increased them by 45% and 42% [14,15].
Sikjaer et al. performed a 24-h monitoring study, analyzing
the effects of rhPTH (1–84) in 38 patients with hypoparathyr-
oidism who had previously completed a 6-month randomized
study on effects of treatment with a fixed rhPTH (1–84) dose of
100 µg/day or similar placebo as an add-on to conventional
treatment. rhPTH (1–84) changed the diurnal rhythms of
ionized calcium levels and 1,25(OH)2D levels, with rising levels
following injection. In 71% of the rhPTH (1–84) treated
patients, asymptomatic hypercalcemia was seen. Compared
with placebo, 24-h urinary calcium, phosphate, and magne-
sium did not change, although the diurnal variation in renal
excretion rates changed significantly in response to treatment.
In this study a 100-µg daily dose of rhPTH (1–84) appeared to
be too high in some patients, suggesting a need for a device
allowing for individual dose adjustments [9].
In contrast to the effect of rhPTH (1–84) treatment in
patients with osteoporosis, in hypoparathyroidism it causes a
decrease in bone mineral density (BMD) and a marked
increased bone turnover, with a pathological state of over-
mineralized bone and, during long-term treatment, may deter-
mine a more physiologic bone metabolism [16]. A study
showed effects of rhPTH (1–84) (100 mg/day subcutaneously)
on bone microstructure, as assessed by micro-computed
tomography (mCT), with iliac crest bone biopsies of patients
with hypoparathyroidism after 24 weeks of treatment.
Compared with placebo, PTH caused a 27% lower trabecular
thickness (p < 0.01), a 4% lower trabecular bone tissue density
(p < 0.01), and connectivity density was 34% higher (p < 0.05).
The number of Haversian canals per area, at cortical bone, was
139% higher in the group treated with rhPTH (1–84), with an
increased cortical porosity. Areal BMD (aBMD) and volumetric
BMD (vBMD), at different subregions of the hip, decreased
significantly by 1–4% in the patients treated with rhPTH (1–
84), as assessed by dual-energy X-ray absorptiometry (DXA)
and quantitative computed tomography (QCT). However, at
the lumbar spine, aBMD decreased by 1.8% (p < 0.05), whereas
vBMD increased by 12.8% in the group treated with PTH
compared with the placebo group [17]. Moreover, Rubin
et al. showed that rhPTH (1–84) stimulated the increase of
the number and maturity of circulating osteogenic cells and
histomorphometric indices of bone formation in patients
affected by hypoparathyroidism, thus explaining, at least in
part, the role of the PTH bone anabolic [18,19].
2.4. Pharmacokinetics
Peak plasma concentration (mean Tmax) after single subcuta-
neous injections of rhPTH (1–84) at 50 and 100 μg in subjects
affected by hypoparathyroidism occurs within 5–30 min, and a
second usually smaller peak at 1–2 h [14,15]. PTH levels
become undetectable by 12 or 24 h [15]. The plasma AUC
increases in a dose-proportional manner from 50 to 100 μg,
and the apparent terminal half-life (t1/2) is 3.02 and 2.83 h for
the 50 and 100 μg dose, respectively. One 100-μg dose of
rhPTH (1–84) provides a 24-h calcemic response in hypopar-
athyroidism subjects [14].
rhPTH (1–84) administered subcutaneously has an absolute
bioavailability of 53%, and a volume of distribution of 5.35 L at
steady state. Physiologically, once secreted, PTH is rapidly
cleared from plasma through uptake, principally by the liver
and kidney, where PTH (1–84) is cleaved into amino- and
carboxyl-terminal fragments that are then cleared by the kid-
ney [20]. Currently, no dose adjustment for rhPTH (1–84) is
required for patients with mild to moderate renal or hepatic
impairment, and no studies were conducted in patients with
severe renal impairment or in renal impairment patients on
dialysis [14]. Pharmacokinetic analyses have shown that age,
sex, race, and body weight did not significantly affect the
pharmacokinetics of this drug [14].
The recommended starting dose is 50 µg and, based on
calcemic response, can be titrated at 2–4-week intervals
upward to doses of 75 µg and then 100 µg. It is intended to
be self-administered once daily by subcutaneous injection into
alternating thighs [11].
3. Clinical efficacy
3.1. Phase II study
In a Danish randomized controlled, double-blind study, rhPTH
(1–84) or placebo was administrated in a fixed dose of 100 μg
in 62 patients for 24 weeks. Compared with placebo, patients
treated with rhPTH (1–84) reduced their daily dose of calcium
and active vitamin D significantly, by 75% and 73%, respec-
tively, without developing hypocalcemia. However, hypercal-
cemia occurred frequently during the down titration of
calcium and active vitamin D. Plasma phosphate and renal
calcium and phosphate excretion did not change.
Furthermore, this treatment significantly increased plasma
levels of bone turn-over markers, whereas BMD decreased at
the hip, lumbar spine, and whole body, but not at the fore-
arm [16].
3.2. Phase III studies
Further data from five studies, have been published on effects
of replacement therapy with rhPTH (1–84) in hypoparathyroid-
ism [21–25].
Rubin et al. investigated the use of the rhPTH (1–84) in a
fixed dose of 100 μg every other day by subcutaneous injec-
tion in 30 subjects with hypoparathyroidism in an open-label
study for 24 months, with monitoring of calcium and vitamin
D supplementation requirements, serum, and 24 h urinary
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calcium excretion, and BMD by DXA. Requirements for supple-
mental calcium decreased significantly by 45%, as did require-
ments for supplemental 1,25(OH2)D3, by 41%. Serum calcium
levels and 24 h urinary calcium excretion were mostly
unchanged at 24 months. BMD increased at the lumbar
spine by 2.9 ± 4% from baseline, while femoral neck BMD
remained unchanged and distal one third radial BMD
decreased by 2.4 ± 4% [21].
Similarly, Cusano et al. [22] studied the effect of 4 years
of rhPTH (1–84) treatment in 27 adults with hypoparathyr-
oidism. Replacement therapy reduced supplemental calcium
requirements by 37% and active vitamin D by 45%. Seven
subjects were able to stop 1,25(OH2)D3 completely. Serum
calcium levels remained stable, and urinary calcium and
phosphorus excretion decreased. Lumbar spine BMD
increased by 5.5 ± 9% at year 4. Femoral neck and total
hip BMD remained stable. At year 4, distal radius BMD was
not different from baseline. Bone turnover markers increased
significantly, reaching a threefold peak from baseline values
at 6–12 months, subsequently declining to steady-state
levels at 30 months. This is the first study to report the
extended use of any PTH therapy in a well-described cohort
over 4 years. Subsequently, Cusano et al. demonstrated that
rhPTH (1–84) therapy is not only associated with improve-
ment in biochemical and skeletal indices, but also in mental
and physical health as determined by the RAND 36-Item
Short Form (SF-36) Health Survey [26,27].
In REPLACE, a double-blind, placebo-controlled, rando-
mized phase 3 study [23], 134 patients with hypoparathyroid-
ism were randomly assigned to 50 μg per day of rhPTH (1–84)
or placebo for 24 weeks. Active vitamin D and calcium were
progressively reduced, while rhPTH (1–84) could be titrated up
from 50 to 75 μg and then 100 μg. Compliance with injection
was excellent for both groups, with 80% or higher compliance
in 88 (98%) of 90 patients in the rhPTH (1–84) group and 42
(96%) of 44 patients in the placebo group. The primary end-
point of the study was the proportion of patients at week 24
who achieved a 50% or greater reduction from baseline in
their daily dose of oral calcium and active vitamin D, while
maintaining a serum calcium concentration greater than or
the same as baseline concentration and less than or equal to
the upper limit of normal. This endpoint was achieved by 53%
of patients in the rhPTH (1–84) group compared with 2% in
the placebo group. In the rhPTH (1–84) group, the mean dose
of oral calcium supplementation and active vitamin D
decreased respectively by 52% and 78%, and, in the hip
region, there was also a significant decline in BMD. In the
rhPTH (1–84) group, albumin-corrected serum calcium con-
centrations increased at the start of treatment, despite large
reductions in both oral calcium and active vitamin D doses,
whereas urinary calcium excretion showed a slight decrease.
In the placebo group, on the other hand, total serum calcium
concentrations fell rapidly and remained close to the lower
end of the target range for the duration of the study; mean
urinary calcium excretion rate also decreased. Mean serum
phosphate levels were similar (at the upper limit of normal)
in both groups at baseline, but decreased in the group treated
with rhPTH (1–84) and remained lower than in the placebo
group. This is the first study to use a flexible dosing regimen
of rhPTH (1–84) and a rigorous algorithm for titration of oral
calcium and active vitamin D [23].
Subsequently, it has been conducted a 24-week, open-
label, flexible-dose extension study of REPLACE, named
REPEAT. Patients who previously completed or enrolled in
REPLACE received rhPTH (1–84), 50 μg/day, escalated to 75
and then to 100 μg/day, if required. The primary endpoint was
≥50% reduction in oral calcium (or ≤500 mg/day) and active
vitamin D (or calcitriol ≤0.25 μg/day or alfacalcidol ≤0.50 μg/
day), maintaining normocalcemia. Twenty-four patients, of
which 16 previously treated with rhPTH (1–84), and 8 rhPTH
(1–84)-naïve, were enrolled and completed the study. At study
end, 75% of patients achieved the study endpoint, and 58%
eliminated oral calcium and active vitamin D. Urinary calcium,
serum phosphate, and calcium–phosphate product decreased
by the study end, and mean serum bone turnover markers
increased with rhPTH (1–84, [24]).
Rubin et al. have recently published an important prospec-
tive open-label study of 33 subjects with hypoparathyroidism,
treated with rhPTH (1–84) subcutaneous (starting dose of 100
µg every other day) for 6 years [25]. This study reports the
longest clinical experience with PTH treatment available so far
in the management of hypoparathyroidism. The use of a long-
term, continuous therapy with rhPTH (1–84), in this popula-
tion, has been associated with a significant reduction of sup-
plemental calcium and calcitriol requirements, maintaining
stable serum calcium levels, reducing urinary calcium excre-
tion and with a good safety profile. Serum phosphate
decreased significantly from baseline at years 4 and 5, but
year-6 levels were similar to baseline values. Lumbar spine
and total hip BMD increased, whereas femoral neck BMD
remained stable and the distal one-third radius decreased.
Bone turnover markers increased significantly, and subse-
quently declining but remaining higher than pretreatment
values [25].
Table 1 shows the results of the studies shown so far.
4. Safety and tolerability
The REPLACE study tested, in addition to efficacy, also safety
and tolerability of a once-daily flexible dose (50, 75, or 100 μg)
regimen of rhPTH (1–84) in adults with hypoparathyroidism
[23]. All 134 patients were included in the safety analyses, and
the overall incidence of adverse events was similar in both
groups, treated with rhPTH (1–84) and placebo group. Ten
(11%) of the patients in the rhPTH (1–84) group and four
(9%) in the placebo group had serious adverse events. In the
rhPTH (1–84) group, only one serious adverse event, charac-
terized by hypercalcemia, was regarded as treatment related.
In both groups, no significant changes in cardiovascular vari-
ables (blood pressure, heart rate, or QTc interval), or renal
variables, such as serum creatinine or estimated creatinine
clearance, were described. During the treatment period, hypo-
calcaemia was reported as an adverse event in 23 (26%)
patients in the rhPTH (1–84) group (43 events) compared
with nine (21%) patients in the placebo group (nine events).
The rhPTH (1–84) treatment was generally well tolerated. Data
derived by the cohort study of subjects treated through
4 years have not raised any safety concerns [22], although
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further long-term data are necessary. With regard to hypercal-
cemia, it may occur early in the treatment course and is easily
remedied by reducing supplemental calcium and active vita-
min D [23]. Subsequently, the extension study REPEAT did not
show serious adverse events [24].
The longest experience with the therapeutic use of PTH
[25] for 6 years has demonstrated, although in a small sample,
safety regarding the control of calcium homeostasis (12 hyper-
calcemic events in 9 subjects; 2.5% of all values), without
hypercalcemic events requiring hospitalization. Moreover,
many adverse events (i.e. nausea, headache, musculoskeletal,
fatigue, dizziness, neurologic, mental and mood, paresthesia,
and increased urination) seemed to diminish after the first
year of therapy. The most common serious adverse event
was hypocalcemia (five times in three patients), and other
adverse events included eight fractures in six patients [25].
Therefore, the hypercalcemic and hypocalcemic events
described have been very uncommon.
In a study, osteosarcoma has occurred in rats treated with
PTH, given subcutaneously at doses of 10, 50, and 150 μg/kg/
day [14,27,28]. These doses were respectively 3–71 times
higher than systemic exposure described in humans following
a subcutaneous dose of 100 μg/day based on AUC. In addition
to dose, bone metabolism in the rat differs from that in
humans, and the different physiology may account for the
increased incidence of osteosarcoma in rats [29]. Therefore,
Table 1. Studies on effects of replacement therapy with rhPTH (1–84) in hypoparathyroidism.
Study Participants Trial Outcomes Trials
Reference
Subjects
Age (years)
Study design
PTH peptides
Dosage
Duration
Serum calcium
Urinary calcium
BTM
BMD
Results in treated
rhPTH (1–84) Strength Limitation
Rubin
et al.
[21]
30 adult
Age: 25–68 years
Open label
Every other day
PTH (1–84) s.c.
(100 μg)
2 years
Calcium dose
1–25(OH)2
D dose
S-calcium
U-calcium
BTM
BMD
↓
↓
=
=
N/A
↑ Lumbar spine
↓1/3 distal radius
= Femoral neck
Duration No control
arm, open
label
Sikjaer
et al.
[16]
62 adult
age: 25–80 years
Double-blind
Randomized,
Placebo-controlled
Once per day
PTH (1–84) s.c.
(100 μg) vs.
Calcium and 1–25(OH)2 D
24 weeks
Calcium dose
1–25(OH)2
D dose
S-calcium
U-calcium
BTM
BMD
↓
↓
=
=
↑
↓ Lumbar spine,
hip, femoral neck
Large number, double blind Duration
Cusano
et al.
[22]
27 adult
age: 25–68 years
Open label
Every other day
PTH (1–84) s.c.
(starting dose 100 μg)
4 years
Calcium dose
1–25(OH)2
D dose
S-calcium
U-calcium
BTM
BMD
↓
↓
=
↓
↑
↑ Lumbar spine
= Hip, femoral
neck, distal radius
Duration No control
arm, open
label
Mannstad
et al.
[23]
134 adult
age: 18–85 years
Double-blind
Randomized
Placebo-controlled
Once per day
PTH (1–84) s.c.
(starting dose 50 μg) vs.
calcium and 1–25(OH)2 D
24 weeks
Calcium dose
1–25(OH)2
D dose
S-calcium
U-calcium
BTM
BMD
↓
↓
=
=
N/A
N/A
Flexible dosing and titration
algorithm, large number, double
blind
Short term
Defined-
dose
schedule
Lakatos
et al.
[24]
24 adult
Age: 18–85 years
Open-label, flexible-dose
extension study of
REPLACE
once per day
PTH (1–84) s.c.
(starting dose 50 μg)
24-weeks
Calcium dose
1–25(OH)2
D dose
S-calcium
U-calcium
BTM
↓
↓
=
↓
↑
Flexible dosing and titration No control
arm, open
label
Rubin
et al.
[25]
33 adult
age: 45–49 years
Prospective open-label study,
every other day
PTH (1–84) s.c.
(starting dose 100 μg,)
6 years
Calcium dose
1–25(OH)2
D dose
S-calcium
U-calcium
BTM
BMD
↓
↓
=
↓
↑
↑ Lumbar spine,
total hip
= Femoral neck
↓ Third radius
Duration No control
arm, open
label
BTM: bone turn-over markers; BMD: bone mineral density; S: serum; U: urinary; ↑: increase; ↓: decrease; N/A: not available.
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the relevance of these animal findings to humans is uncertain.
Moreover, with over 10 years of clinical post-approval experi-
ence with PTH (1–34) and 7 years with rhPTH (1–84) for treat-
ment of osteoporosis, no adverse signals of osteosarcoma
have been observed [29,30]. Results from clinical trials with
cumulative numbers of 16,000 subjects treated with up to
3 years of continuous therapy have not reported any skeletal
malignancies [31–33]. The ‘black box’ warning for rhPTH (1–84)
thus reiterates this cautionary note although rhPTH (1–84) has
no therapeutic time limit for treatment.
No effect on fertility was described in male and female rats
given PTH at doses up to 1000 μg/kg/day (120 times systemic
exposure after a clinical dose of 100 μg/day).
However, no adequate studies in women exist for the use of
rhPTH (1-84) during pregnancy and lactation. A peri-/post-natal
study in pregnant rats treated with the drug (100, 300, 1000 μg/
kg/day, subcutaneous) observed developmental effects from
organogenesis through lactation, while entire stillborn litters
were described in the 300 μg/kg/day group (34 times the
100 μg/day clinical dose based on AUC) [17]. In pups from litters
in the 100 μg/kg/day group (10 times the 100 μg/day clinical
dose based on AUC) was observed an increased incidence of
morbidity associated with dehydration, broken palate and
palate injuries related to incisor misalignment and mortality
[17]. Since animal studies are not always predictive of human
response, and actually the effects of rhPTH (1-84) during preg-
nancy and breastfeeding are unknown, the drug should be not
used during pregnancy or lactation.
At last, safety and efficacy in patients less than 18 years of
age has not been established, and the use of rhPTH (1–84) is
to be avoided in case of pediatric and young adult patients
with open epiphyses, considering the increased baseline risk
for osteosarcoma [14].
5. Conclusions
Conventional therapy of hypoparathyroidism cannot resolve
all problematic aspects of this disease, such as, in some cases a
not adequate control of serum and urinary calcium home-
ostasis, an abnormal bone remodeling (low abnormal bone
turnover, with impairment of bone quality), a poor compliance
to therapy, and a consequent reduced quality of life.
Moreover, large doses of calcium and active vitamin D supple-
ments are associated to long-term risks of nephrolithiasis,
nephrocalcinosis, renal impairment, cataracts, and cerebral
calcifications.
The recent FDA approval of rhPTH (1–84) is a fundamental
step in the treatment of hypoparathyroidism, for patients not
well controlled with standard treatment. This drug provides
the natural hormone, which is lacking in this disease and
permits major reductions in the need for calcium and active
vitamin D supplements, maintaining normal calcium levels. In
the studies conducted so far on rhPTH (1–84) for hypopar-
athyroidism, it indeed, has shown an improved calcium home-
ostasis, a reduction of 24-h calcium excretion, and an
improvement in quality of life. Moreover, therapy with rhPTH
(1–84) tends to reverse the state of low bone turnover with a
marked increased bone turnover and restoration of normal
bone physiology. Finally, the drug has a potential preventive
role for other complications such as nephrolithiasis, nephro-
calcinosis, cataracts, and cerebral calcifications, given, of
course, the drug effect on calcium–phosphorus homeostasis.
Nevertheless, in the future further studies will have to be
performed to evaluate long-term efficacy and safety of the
drug, given the chronic nature of the disease.
6. Expert opinion
The key findings in the research done in this field, so far, are
the evident demonstration of a good control of calcium home-
ostasis by rhPTH (1–84), an important reduction of calcium
and active vitamin D requirements, and a reversal of the state
of low bone turnover typical of hypothyroidism.
On the other side, the weaknesses in the research done so far
are the duration of the studies carried out until now, given the
chronic nature of the disease and the need for PTH therapy over
years, the numerousness of samples, the lack of the clarification
of the effect on the control of serum phosphorus levels, the
limitation of the outcomes assessed such as long-term compli-
cations, including extra-skeletal calcifications, nephrolithiasis
and nephrocalcinosis, bone strength, and fracture risk.
Furthermore, long-term effects regarding quality of life and
neurocognitive function require further studies. Impairment of
well-being probably results directly from PTH deﬁciency with-
out the involvement of changes in calcium homeostasis. It is
known that PTH, speciﬁcally, binds to the PTH2 receptor,
expressed in several brain regions, however, another brain-
speciﬁc ligand to the PTH2 receptor, a hypothalamic neuro-
peptide (tuberoinfundibular peptide of 39 residues), has been
described [34,35]. Moreover, the expression of 25-hydroxyvita-
min D-1 alpha-hydroxylase has recently been demonstrated in
brain tissue [36]. Therefore, its role in the central nervous
system remains to be determined.
With regard to the effect of drug on BMD, the longest
experience of continuous therapy for 6 years with rh PTH (1–
84) has showed that BMD at lumbar spine and total hip, above
average at baseline, increased throughout the study period,
whereas BMD at the femoral neck was unchanged. BMD at the
distal one third radius site progressively decreased [25]. As
cited by the authors, these densitometric results are explain-
able considering the differential effects of PTH at these differ-
ent sites (predominantly cortical or trabecular). Furthermore,
histomorphometric analysis of bone biopsies after 2 years
showed that trabeculae were thinner and more numerous,
and showed an increase of cortical porosity [25]. It is possible
that the salutary effects on microarchitecture and bone size
could provide biochemical advantages at cortical bone despite
a decrease in BMD, but further long-term investigations
should be performed on microstructural features of bone
tissue in patients treated with rhPTH (1–84). Moreover, it
should be clarified whether the fracture events, described in
this study, were associated to natural history of hypoparathyr-
oidism, rather than due to rhPTH (1–84) treatment.
Data based on available studies up to now show a good
safety profile of PTH in replacement therapy, but the FDA has
approved rhPTH (1–84) with a ‘black box’ warning because of
the history of rat osteosarcoma using all forms of PTH that
have been studied so far, without limit of the duration of use.
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In particular, the use of rhPTH (1-84) should be avoided in
patients who have risk factors for osteosarcoma unless the
benefits of using rhPTH (1-84) in these patients are deter-
mined to outweigh this potential risk. In future years, consid-
ering this potential long-term risk of osteosarcoma for
humans, additional safety data should be collected.
rhPTH (1–84) has the advantage, due to its pharmacoki-
netics, that it can be administered just once a day. However,
the ultimate goal of future research in this filed is to identify
the optimal treatment regime, that actually require further
clarifications. In particular, further investigations are necessary
regarding ideal dosages and administration regimens for PTH,
such as other delivery systems that do not require subcuta-
neous injection, or more physiologic delivery systems, such as
continuous delivery by pump.
At last, in the coming years, thanks to the recent FDA
approval of rhPTH (1–84), it will be possible to perform studies
on larger patient samples, divided by type of hypoparathyr-
oidism, severity, duration of disease, with a longer duration
than what has been done so far, allowing to clarify all the
above mentioned clinical outcomes and profile of safety of
long-term medication.
Funding
This manuscript has not been funded.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any
organization or entity with a financial interest in or financial conflict with
the subject matter or materials discussed in the manuscript. This includes
employment, consultancies, honoraria, stock ownership or options, expert
testimony, grants or patents received or pending, or royalties.
ORCID
Gemma Marcucci http://orcid.org/0000-0003-0579-0542
References
Papers of special note have been highlighted as either of interest (•) or of
considerable interest (••) to readers.
1. Bilezikian JP, Khan A, Potts JT Jr, et al. Hypoparathyroidism in the
adult: epidemiology, diagnosis, pathophysiology, target-organ
involvement, treatment, and challenges for future research. J
Bone Miner Res. 2011;26:2317–2337. doi:10.1002/jbmr.483.
• This article is a comprehensive summary of all aspects regard-
ing hypoparathyroidism.
2. Shoback D. Clinical practice. Hypoparathyroidism. N Engl J Med.
2008;359:391–403. doi:10.1056/NEJMoa0801936.
3. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J
Med. 2000;343:1863–1875. doi:10.1056/NEJM200012213432508.
4. Pearce SH, Williamson C, Kifor O, et al. A familial syndrome of
hypocalcemia with hypercalciuria due to mutations in the cal-
cium-sensing receptor. N Engl J Med. 1996;335:1115–1122.
doi:10.1056/NEJM199610103351505.
5. Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypo-
parathyroidism: summary statement and guidelines. J Clin
Endocrinol Metab. 2016;101:2273–2283. doi:10.1210/jc.2016-1483.
• This article is a summary of current knowledge and recent
advances in the management of hypoparathyroidism.
6. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of
patients with hypoparathyroidism. J Clin Endocrinol Metab.
2012;97:4507–4514. doi:10.1210/jc.2012-1808.
7. Winer KK, Sinaii N, Peterson D, et al. Effects of once versus twice-
daily parathyroid hormone 1-34 therapy in children with hypopar-
athyroidism. J Clin Endocrinol Metab. 2008;93:3389–3395.
doi:10.1210/jc.2007-2552.
8. Albright F, Ellsworth R. Studies on the physiology of the parathyr-
oid glands: I. Calcium and phosphorus studies on a case of idio-
pathic hypoparathyroidism. J Clin Investig. 1929;7(183):201.
doi:10.1172/JCI100224.
9. Sikjaer T, Amstrup AK, Rolighed L, et al. PTH(1-84) Replacement
therapy in hypoparathyroidism: a randomized controlled trial on
pharmacokinetic and dynamic effects after 6 months of treat-
ment. J Bone Miner Res. 2013;28:2232–2243. doi:10.1002/
jbmr.1964.
10. Chu NN, Li XN, Chen WL, et al. Pharmacokinetics and safety of
recombinant human parathyroid hormone (1-34) (teriparatide)
after single ascending doses in Chinese healthy volunteers.
Pharmazie. 2007;62:869–871.
11. Natpara package insert. [cited 2015 Jun 22]. Available from: http://
www.accessdata.fda-.gov/drugsatfda_docs/label/192015/
125511s000lbl.pdf.
12. Khundmiri SJ, Murray RD, Lederer E. PTH and vitamin D. Compr
Physiol. 2016;15(6):561–601.
13. Goltzman D, Karaplis AC. The PTH/vitmina D/FGF 23 axis. In: Brandi ML,
Brown EM, editors. Hypoparthyroidism. Milan: Springer; 2015. p. 69–79.
14. US FDA. Natpara (parathyroid hormone) for injection: US prescrib-
ing information. 2015. [cited 2015 Jun 22]. Available from: http://
www.fda.gov/.
15. Clarke BL, Kay Berg J, Fox J, et al. Pharmacokinetics and pharma-
codynamics of subcutaneous recombinant parathyroid hormone
(1–84) in patients with hypoparathyroidism: an open-label, single-
dose, phase I study. Clin Ther. 2014;36:722–736. doi:10.1016/j.
clinthera.2014.04.001.
16. Sikjaer T, Rejnmark L, Rolighed L, et al. The Effect of Adding PTH(1–
84) to conventional treatment of hypoparathyroidism: a rando-
mized, placebo-controlled study. J Bone Miner Res. 2011;26:2358–
2370. doi:10.1002/jbmr.470.
17. Sikjaer T, Rejnmark L, Thomsen JS, et al. Changes in 3-dimensional
bone structure indices in hypoparathyroid patients treated with
PTH(1-84): a randomized controlled study. J Bone Miner Res.
2012;27:781–788. doi:10.1002/jbmr.1493.
18. Rubin MR, Manavalan JS, Dempster DW, et al. Parathyroid hor-
mone stimulates circulating osteogenic cells in hypoparathyroid-
ism. J Clin Endocrinol Metab. 2011;96:176–186. doi:10.1210/
jc.2009-2682.
19. Rubin MR, Dempster DW, Sliney J Jr, et al. PTH(1-84) administration
reverses abnormal bone-remodeling dynamics and structure in
hypoparathyroidism. J Bone Miner Res. 2011;26:2727–2736.
doi:10.1002/jbmr.452.
20 Isaia G, Marchetti M. PTH and PTH-related peptides. In: Brandi ML,
Brown EM, editors. Hypoparathyroidism. Milan: Spring; 2015. p. 19–24.
21. Rubin MR, Sliney J Jr, McMahon DJ, et al. Therapy of hypoparathyr-
oidism with intact parathyroid hormone. Osteoporos Int.
2010;21:1927–1934. doi:10.1007/s00198-009-1149-x.
22. Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypopar-
athyroidism with PTH(1-84): a prospective four-year investigation
of efficacy and safety. J Clin Endocrinol Metab. 2013;98:137–144.
doi:10.1210/jc.2012-2984.
•• Pivotal trial, extension study of REPLACE.
23. Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of
recombinant human parathyroid hormone (1–84) in hypoparathyr-
oidism (REPLACE): a double blind, placebo-controlled, randomized,
phase III study. Lancet. 2013;1::275–283.
24. Lakatos P, Bajnok L, Lagast H, et al. An open-label extension study
of parathyroid hormone rhPTH(1-84) in adults with hypoparathyr-
oidism. Endocr Pract. 2016;22:523–532. doi:10.4158/EP15936.OR.
25. Rubin MR, Cusano NE, Fan WW, et al. Therapy of hypoparathyroid-
ism with PTH(1-84): a prospective six year investigation of efficacy
EXPERT OPINION ON BIOLOGICAL THERAPY 1423
and safety. J Clin Endocrinol Metab. 2016;101:2742–2750.
doi:10.1210/jc.2016-1483.
•• Pivotal trial of rhPTH (1–84).
26. Cusano NE, Rubin MR, McMahon DJ, et al. PTH(1-84) is associated
with improved quality of life in hypoparathyroidism through 5
years of therapy. J Clin Endocrinol Metab. 2014;99:3694–3699.
doi:10.1210/jc.2014-2267.
•• This study is the longest experience with the therapeutic use of
rhPTH (1–84) in hypoparathyroidism.
27. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily
subcutaneous injections of recombinant human parathyroid hor-
mone (1-34) for 2 years and relevance to human safety. Toxicol
Pathol. 2002;30:312–321. doi:10.1080/01926230252929882.
28. Jolette J, Wilker CE, Smith SY, et al. Defining a noncarcinogenic
dose of recombinant human parathyroid hormone 1-84 in a 2-year
study in Fischer 344 rats. Toxicol Pathol. 2006;34:929–940.
doi:10.1080/01926230601072301.
29. Capriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a
decade of experience. J Bone Miner Res. 2012;27:2419–2428.
doi:10.1002/jbmr.1800.
30. Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing
surveillance study of adult osteosarcoma and teriparatide: study
design and findings from the first 7 years. J Bone Miner Res.
2012;27:2429–2437. doi:10.1002/jbmr.1768.
31. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide
[human parathyroid hormone (1-34)] therapy on bone density in
men with osteoporosis. J Bone Miner Res. 2003;18:9–17.
doi:10.1359/jbmr.2003.18.2.195.
32. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide
versus alendronate for treating glucocorticoid-induced osteoporo-
sis: thirty-six-month results of a randomized, double-blind, con-
trolled trial. Arthritis Rheum. 2009;60:3346–3355. doi:10.1002/
art.24879.
33. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant
human parathyroid hormone (1-84) on vertebral fracture and bone
mineral density in postmenopausal women with osteoporosis: a
randomized trial. Ann Intern Med. 2007;146:326–339. doi:10.7326/
0003-4819-146-5-200703060-00005.
34. Usdin TB, Gruber C, Bonner TI. Identiﬁcation and functional expres-
sion of a receptor selectively recognizing parathyroid hormone, the
PTH2 receptor. J Biol Chem. 1995;270:15455–15458. doi:10.1074/
jbc.270.26.15455.
35. Usdin TB, Hoare SR, Wang T, et al. TIP39: a new neuropeptide and
PTH2-receptor agonist from hypothalamus. Nat Neurosci.
1999;2:941–943. doi:10.1038/14724.
36. Fu GK, Lin D, Zhang MY, et al. Cloning of human 25-hydroxyvitamin
D-1 alpha-hydroxylase and mutations causing vitamin
D-dependent rickets type 1. Mol Endocrinol. 1997;11:1961–1970.
1424 G. MARCUCCI ET AL.
